Description of Research Expertise:
Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research.
Cuchel M, Raper AC, Pryma DA, Freifelder RH, Poria R, Cromley D, Li X, Dunbar RL, French B, Qu L, Farver W, Su C-C, Lund-Katz S, Baer A, Ruotolo G, Akerblad P, Ryan CS, Xiao L, Kirchgessner TG, Millar JS, Billheimer JT, Rader DJ: A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans J Lipid Res : 2017.
Ueda M*, Dunbar RL*, Wolska A, Sikora TU, del Rosario Escobar M, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, Remaley AT, Rader DJ: A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency with Severe Triglyceridemia and Pancreatitis J Clin Endocrinol Metab 102 : 2017.
Dunbar RL*, Goel H*, Tuteja S, Song W-L,
Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL: Measuring Physical Stigmata of Niacin-Associated Skin Toxicity by Colorimetry, White-Light Spectroscopy, Laser Doppler Flowmetry, and Thermometry in Combination with Symptom Perception Scoring: Methods to Aid Development of Niacin Mimetics J Lipid Res : 2017.
Dewey FE*, Gusarova V*, Dunbar RL*, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV , Bruse S, Dansky HM , Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH , Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-D I on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM: Genetic and Pharmacologic Inactivation of ANGPTL3 and Atherosclerotic Cardiovascular Disease NEJM : 2017.
Dunbar RL, Bouzelmat A, Gipe DA, Pordy R, Sasiela W, Mellis S, Banerjee P: Inhibition Of ANGPTL3 By Evinacumab Reduced Triglycerides (TGs) And LDL-C In Subjects Presenting With Modest Elevations In TGs And/or LDL-C, Recapitulating The Hypolipidemic Effects Of Loss-of-function (LoF) Mutations Of ANGPTL3 Circulation : 2016.
Digenio A*, Dunbar RL*, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Diabetes Care 39 (8): 1408-1415,2016.
Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE: Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH American Journal of Medicine 129 (7): 2016.
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes Journal of Clinical Lipidology 10 (3): 2016.
Goel H, Dunbar RL: Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. Curr Atheroscler Rep 18 (4): 17,2016.
Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan JS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN: Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein Arterioscler Thromb Vasc Biol 36 : 2016.
View all publications